Abstract
Background
Telangiectasia macularis eruptiva perstans (TMEP) is a rare form of cutaneous mastocytosis (CM). Although TMEP has been traditionally thought to be restricted to the skin, a recent retrospective multicentric study established a diagnosis with systemic involvement of mastocytosis in 47% patients affected by TMEP and aggressive systemic mastocytosis in 9%.
Objectives
To evaluate systemic involvement in patients affected by TMEP.
Materials and Methods
We conducted a retrospective monocentric study among patients affected by TMEP visited in our dermatology clinic. Data regarding gender, age at diagnosis, duration of the disease before diagnosis, topography, clinical features, presence of extra-cutaneous symptoms, serum tryptase levels, and histopathological and bone marrow biopsy features were analysed.
Results
Among 119 patients classified with mastocytosis, eight patients (six males, two females) with TMEP and one female patient affected by mastocytosis in the skin, a TMEP variant, were retrospectively studied. The mean diagnostic delay was two years (range: 8–26 months). In two patients (25%), bone marrow involvement was identified and osteoporosis and hepatosplenomegaly were also found. The two patients with systemic involvement exhibited a statistically significant increase in serum tryptase levels (p <0.05). The detection of KIT gene mutation in skin specimens revealed a somatic mutation, KITD816 V, only in these two patients.
Conclusion
TMEP is a rare form of CM, often neglected. A correct and early diagnosis of TMEP is important to rule out systemic involvement of the disease. Detection of serum tryptase levels may be a useful, rapid, and non-invasive marker of systemic involvement.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Longley J, Duffy TP, Kohn S. The mast cell and mast cell disease. J Am Acad Dermatol 1995;32:545–61.
Hartmann K, Henz BM. Mastocytosis: recent advances in defining the disease. Br J Dermatol 2001; 144: 682–95.
Hartmann K, Escribano L, Grattan C, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol 2016; 137: 35–45.
Valent P, Akin C. Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood 2017;129:1420–7.
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391–405.
Pardanani A. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. Am J Hematol 2013;88:612–24.
Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 2001; 25: 519–28.
Soter NA. The Skin in mastocytosis. J Invest Dermatol 1991;96:S32–9.
Cohn MS, Mahon MJ. Telangiectasia macularis eruptiva perstans. J Am Osteopath Assoc 1994; 94: 246–8.
Tebbe B, Stavropoulos PG, Krasagakis K, Orfanos CE. Cutaneous mastocytosis in adults. Dermatology 1998; 197: 101–8.
Weber FP. Telangiectasia macularis eruptiva perstans-probably a telangiectatic variety of urticaria pigmentosa in an adult. Proc R Soc Med 1930;24:96–7.
Severino M, Chandesris MO, Barete S, et al. Telangiectasia macularis eruptiva perstans (TMEP): a form of cutaneous mastocytosis with potential systemic involvement. J Am Acad Dermatol 2016; 74: 885–91.
Ackerman BA, Böer A, Bennin B, Gottlieb GJ. Istologic Diagnosis of Inflammatory Skin Diseases: an Algorithmic Method Based on Pattern Analysis, 3rd ed. Williams & Wilkins, 2005.
Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603–25.
Ball F. Telangiectasia macularis eruptiva perstans: report of an early stage in a child. Arch Derm Syphilol 1937; 36: 65–9.
Gibbs NF, Friedlander SF, Harpster EF. Telangiectasia macularis eruptiva perstans. Pediatr Dermatol 2000; 17: 194–7.
Watkins CE, Bokor WB, Leicht S, Youngberg G, Krishnaswamy G. Telangiectasia macularis eruptiva perstans: more than skin deep. Dermatol Reports 2011;3:e12.
Vano-Galvan S, Álvarez-Twose I, Heras E, et al. Dermoscopic features of skin lesions in patients with mastocytosis. Arch Dermatol 2011; 147: 932–40.
Sotiriou E, Apalla Z, Ioannides D. Telangiectasia macularis eruptiva perstans successfully treated with PUVA therapy. Photodermatol Photoimmunol Photomed 2010;26:46–7.
Allen BR. Telangiectasia macularis perstans. Br J Dermatol 1978; 99: 28–9.
Tumer G, Jow T, McElligott S, Schwartz RA, Lambert WC. Telangiectasia macularis eruptiva perstans: report of three cases. Skinmed 2017; 15: 171–4.
Tharp MD. The spectrum of mastocytosis. Am J Med Sci 1985; 289: 119–32.
Periasamy B. Telangiectasia macularis eruptiva perstans rapidly progressing to systemic mastocytosis. J Am Acad Dermatol 2018; 52: P61.
Sarkany RPE, Monk BE, Handfield-Jones SE. Telangiectasia macularis eruptiva perstans: a case report and review of the literature. Clin Exp Dermatol 1998; 23: 38–9.
Akiyama M. A clinical and histological study of urticaria pigmentosa: relationships between mast cell proliferation and the clinical and histological manifestations. J Dermatol 1990; 17: 347–55.
Kalayciyan AK, Kotogyan A. Telangiectasia macularis eruptiva perstans. J Eur Acad Dermatol Venereol 2001; 15: 263–4.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Michelerio, A., Grassi, S., Elena, C. et al. Telangiectasia macularis eruptiva perstans: a neglected type of mastocytosis with exclusively cutaneous involvement? A case series. Eur J Dermatol 29, 174–178 (2019). https://doi.org/10.1684/ejd.2019.3532
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2019.3532